Literature DB >> 27456877

Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis.

Soheil Tavakolpour1.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is considered as the most common chronic inflammatory neurologic disorder diagnosed in young adults. Both environmental and genetic factors may influence risk of MS development. Interleukin 7 receptor (IL7R) is one of the most studied gene polymorphism on MS that may play a possible role in MS development. The most studied polymorphism of IL7R gene is "rs6897932" polymorphism on IL7Rα gene (IL7RA).
METHODS: PubMed, Scopus, and Google scholar databases were searched for all of related studies on the association of IL7RA polymorphism with single nucleotide polymorphism (SNP) ID of "rs6897932" and the risk of MS through August 07, 2015. After exclusion of irrelevant articles, 11 eligible studies were selected, which were analyzed to determine an association between the MS and IL7R T244I polymorphism (rs6897932). For identification of this association, odds ratios (ORs) and 95% confidence interval (95% CI) were calculated. Four models of allelic (T vs. C), co-dominant genotype (TT vs. CC), dominant (TT+CT vs. CC), and recessive genotypes (TT vs. CT+CC) were considered to check the possible role of rs6897932 polymorphism in MS. A sensitivity analysis was conducted to find the reliability of this study. Furthermore, funnel plots were used to evaluate publication bias.
RESULTS: A total of 11 case-control studies were identified through this meta-analysis, which containing 6752 cases and 7349 controls. In overall, the frequency of the C allele was found to be higher in patients with MS compared to healthy controls (75.66% vs. 72.19%). T allele was significantly associated with the decreased risk of MS in a random effect model (T vs. C: OR=0.84, 95% CI=0.77-0.92, P-value <0.001). In the co-dominant, dominant, and recessive genotypes models, a significant association between the IL7R T244I polymorphism and MS risk was demonstrated (TT vs. CC: OR=0.70, 95% CI=0.61-0.80, P-value <0.001; TT+CT vs. CC: OR=0.82, 95% CI=0.73-0.92, P-value <0.001; TT vs. CT+CC: OR=0.76, 95% CI=0.66-0.87, P-value <0.001). Sensitivity analysis revealed that this study is reliable. There was no evidence of publication bias.
CONCLUSION: It was demonstrated that the IL7R T244I polymorphism was associated with susceptibility to MS. However, more well-designed studies with large sample size are needed to validate this association between this single nucleotide polymorphism and MS.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Interleukin 7 receptor; Meta-analysis; Multiple sclerosis; Polymorphisms; Rs6897932

Mesh:

Substances:

Year:  2016        PMID: 27456877     DOI: 10.1016/j.msard.2016.05.001

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  7 in total

1.  Assessment of IL-7RA T244I Polymorphism as a Risk Factor of Multiple Sclerosis in Turkish Population.

Authors:  Miraç Aysen Ünsal; Nüket Yıldız Manukyan; Nihal IŞik; Güher Saruhan Dİreskenelİ
Journal:  Noro Psikiyatr Ars       Date:  2019-08-26       Impact factor: 1.339

Review 2.  A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.

Authors:  Bert A 't Hart; Jordon Dunham; Bart W Faber; Jon D Laman; Jack van Horssen; Jan Bauer; Yolanda S Kap
Journal:  Front Immunol       Date:  2017-07-11       Impact factor: 7.561

Review 3.  Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update.

Authors:  Noushin Lotfi; Rodolfo Thome; Nahid Rezaei; Guang-Xian Zhang; Abbas Rezaei; Abdolmohamad Rostami; Nafiseh Esmaeil
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

4.  Identification of key genes and pathways contributing to artery tertiary lymphoid organ development in advanced mouse atherosclerosis.

Authors:  Xi Zhang; Fayuan Liu; Peng Bai; Nianguo Dong; Chong Chu
Journal:  Mol Med Rep       Date:  2019-02-15       Impact factor: 2.952

5.  Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10.

Authors:  Marcello Moccia; Antonio Capacchione; Roberta Lanzillo; Fortunata Carbone; Teresa Micillo; Giuseppe Matarese; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Brain Sci       Date:  2019-09-27

Review 6.  Soluble IL-7Rα/sCD127 in Health, Disease, and Its Potential Role as a Therapeutic Agent.

Authors:  Priscila O Barros; Tamara K Berthoud; Nawaf Aloufi; Jonathan B Angel
Journal:  Immunotargets Ther       Date:  2021-03-08

Review 7.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.